Histone-modifying Enzymes as Therapeutic Targets in Glioma: Biological Rationale and Translational Findings.

Authors

Briana A Santo, A Karim Ahmed, Samuel Emerson

Published in

Hematology/oncology clinics of North America. Oct 06, 2026. Epub Oct 06, 2026.

Abstract

Histone-modifying enzymes have emerged as therapeutic targets in glioma, particularly H3K27M-altered diffuse midline glioma. This article reviews the biological rationale for targeting these enzymes and summarizes the current preclinical and clinical evidence for histone deacetylase, methyltransferase, and demethylase inhibitors. It also discusses the utility of nonenzymatic agents, including bromodomain and extraterminal inhibitors and dordaviprone, that have achieved similar epigenetic effects in this disease.

PMID:
42838830
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.